Kimia Biosciences Limited manufactures and sells active pharmaceutical ingredients (APIs) in India. The company offers and develops APIs in the categories, including gastrointestinal agent, anti-coagulant, anti-hypertensive, lipid lowering agents, vitamin, anti-histamine, anti-convulsant, central stimulant, anti-diabetic, and anti-bacterial, as well as anti-psychotic, anti-fungal, urologicals, anti-inflammatory, prokinetic agent, cholelithiasis agent, anti-asthmatic, anti-depressant, anti-acne, decongestant, and anti-virals. It exports its products. Kimia Biosciences Limited was formerly known as Laurel Organics Ltd and changed its name to Kimia Biosciences Limited January 2019. The company was incorporated in 1993 and is based in New Delhi, India.
| Current Price | ₹32.84 |
|---|---|
| Market Cap | ₹155 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 20 |
| Return on Equity | 53.70% |
| 52-Week Range | ₹23.20 – ₹86.85 |
| Beta (1Y) | 2.25 |
Kimia Biosciences Ltd is trading at ₹32.84, with a market capitalisation of ₹155 Cr.
Kimia Biosciences Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Medicinal Chemicals and Botanical Products).
Kimia Biosciences Ltd has a P/E of 20 and a return on equity of 53.70%.